LX-2022

N/A

Report date: 2023/10/26 16:49:45

Base Information

Drug NameLX-2022
Drug Alias NameLX-2022
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionTroponin I, cardiac muscle gene transference
TargetsTroponin I, cardiac muscle
Therapy Area/IndicationsCardiomyopathy, Hypertrophic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLEXEO Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesLexeo Therapeutics IncLEXEO Therapeutics
Inactive CompaniesN/A
Active IndicationsCardiomyopathy, Hypertrophic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A